| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 20, 2006
From the Department of Neurology (N.S.), University of Southern California, Los Angeles, Calif; the Stroke Center and Department of Neurology (J.L.S., B.O.), University of California Los Angeles (UCLA) Medical Center, Los Angeles, Calif; the Department of Medicine (M.N.), UCLA Medical Center, Los Angeles, Calif; and the Department of Neurology (B.O.), Olive View UCLA Medical Center, Los Angeles, Calif. * To whom correspondence should be addressed. E-mail: sanossia{at}yahoo.com.
Background and Purpose--This review characterizes the current state of knowledge of high-density lipoprotein (HDL) in relation to stroke. Summary of Review--HDL has anti-atherosclerotic and anti-inflammatory properties and is an important component in atherosclerosis. Serum HDL-cholesterol levels are inversely related to heart disease and stroke risk. There are various established and experimental treatments which can raise serum HDL cholesterol and improve its function. Conclusion--HDL is an emerging target for atherosclerotic stroke treatment with the potential to dramatically impact the care of stroke patients.
Revised on September 26, 2006
Accepted on October 3, 2006
High-Density Lipoprotein Cholesterol. An Emerging Target for Stroke Treatment
Nerses Sanossian MD*;
This article has been cited by other articles:
![]() |
G. C. Newman, H. Bang, S. I. Hussain, and J. F. Toole Association of diabetes, homocysteine, and HDL with cognition and disability after stroke Neurology, November 27, 2007; 69(22): 2054 - 2062. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |